Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months

Kenji Inoue1,3, Mieko Masumoto1,3, Masato Wakakura1, Goji Tomita2, On behalf of the Ochanomizu Ophthalmology Study Group31Inouye Eye Hospital, Tokyo, Japan; 2Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan; 3Ochanomizu Ophthalmology, Tokyo, JapanPurpose: To prospectivel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kenji Inoue, Mieko Masumoto, Masato Wakakura, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/94e35d6ea16e41fc9e64d663d25ad529
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:94e35d6ea16e41fc9e64d663d25ad529
record_format	dspace
spelling	oai:doaj.org-article:94e35d6ea16e41fc9e64d663d25ad5292021-12-02T00:57:13ZOcular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months1177-54671177-5483https://doaj.org/article/94e35d6ea16e41fc9e64d663d25ad5292011-03-01T00:00:00Zhttp://www.dovepress.com/ocular-hypotensive-effect-preservation-of-visual-fields-and-safety-of--a6795https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Kenji Inoue1,3, Mieko Masumoto1,3, Masato Wakakura1, Goji Tomita2, On behalf of the Ochanomizu Ophthalmology Study Group31Inouye Eye Hospital, Tokyo, Japan; 2Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan; 3Ochanomizu Ophthalmology, Tokyo, JapanPurpose: To prospectively evaluate the safety, hypotensive effect, and preservation of visual fields of dorzolamide when added to latanoprost.Subjects and methods: This study included 46 patients (46 eyes) with primary open-angle glaucoma who had been treated with latanoprost. Dorzolamide (1%) was added to latanoprost, and the intraocular pressure (IOP) was monitored before and after 3, 6, and 12 months. The mean deviation shown by Humphrey perimetry was compared before and after twelve months of treatment. Adverse reactions were monitored over the 12-month study period.Results: The mean baseline IOP was 17.2 &plusmn; 3.0 mmHg while those after 3, 6 and 12 months of treatment were 14.9 &plusmn; 3.0 mmHg, 14.5 &plusmn; 3.2 mmHg, and 14.6 &plusmn; 2.6 mmHg respectively (P &lt; 0.0001, 1-&szlig;(power) = 0.9999571). The absolute reduction of IOP and the percent reduction were similar after 3, 6, and 12 months of treatment. The mean deviation on Humphrey perimetry was similar before and after twelve months of treatment. Three patients discontinued dorzolamide therapy due to elevation of IOP and one patient discontinued it because of adverse reactions.Conclusion: Dorzolamide is safe and effective when used for twelve months as add-on therapy to latanoprost for open-angle glaucoma.Keywords: dorzolamide, primary open-angle glaucoma, latanoprost&nbsp; Kenji InoueMieko MasumotoMasato Wakakuraet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 393-396 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Kenji Inoue Mieko Masumoto Masato Wakakura et al Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
description	Kenji Inoue1,3, Mieko Masumoto1,3, Masato Wakakura1, Goji Tomita2, On behalf of the Ochanomizu Ophthalmology Study Group31Inouye Eye Hospital, Tokyo, Japan; 2Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan; 3Ochanomizu Ophthalmology, Tokyo, JapanPurpose: To prospectively evaluate the safety, hypotensive effect, and preservation of visual fields of dorzolamide when added to latanoprost.Subjects and methods: This study included 46 patients (46 eyes) with primary open-angle glaucoma who had been treated with latanoprost. Dorzolamide (1%) was added to latanoprost, and the intraocular pressure (IOP) was monitored before and after 3, 6, and 12 months. The mean deviation shown by Humphrey perimetry was compared before and after twelve months of treatment. Adverse reactions were monitored over the 12-month study period.Results: The mean baseline IOP was 17.2 &plusmn; 3.0 mmHg while those after 3, 6 and 12 months of treatment were 14.9 &plusmn; 3.0 mmHg, 14.5 &plusmn; 3.2 mmHg, and 14.6 &plusmn; 2.6 mmHg respectively (P &lt; 0.0001, 1-&szlig;(power) = 0.9999571). The absolute reduction of IOP and the percent reduction were similar after 3, 6, and 12 months of treatment. The mean deviation on Humphrey perimetry was similar before and after twelve months of treatment. Three patients discontinued dorzolamide therapy due to elevation of IOP and one patient discontinued it because of adverse reactions.Conclusion: Dorzolamide is safe and effective when used for twelve months as add-on therapy to latanoprost for open-angle glaucoma.Keywords: dorzolamide, primary open-angle glaucoma, latanoprost&nbsp;
format	article
author	Kenji Inoue Mieko Masumoto Masato Wakakura et al
author_facet	Kenji Inoue Mieko Masumoto Masato Wakakura et al
author_sort	Kenji Inoue
title	Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
title_short	Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
title_full	Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
title_fullStr	Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
title_full_unstemmed	Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
title_sort	ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/94e35d6ea16e41fc9e64d663d25ad529
work_keys_str_mv	AT kenjiinoue ocularhypotensiveeffectpreservationofvisualfieldsandsafetyofaddingdorzolamidetoprostaglandintherapyfortwelvemonths AT miekomasumoto ocularhypotensiveeffectpreservationofvisualfieldsandsafetyofaddingdorzolamidetoprostaglandintherapyfortwelvemonths AT masatowakakura ocularhypotensiveeffectpreservationofvisualfieldsandsafetyofaddingdorzolamidetoprostaglandintherapyfortwelvemonths AT etal ocularhypotensiveeffectpreservationofvisualfieldsandsafetyofaddingdorzolamidetoprostaglandintherapyfortwelvemonths
_version_	1718403398429048832

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months

Ejemplares similares